Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS
A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and ...
Tag: Myelodysplastic Syndromes
MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to ...
Break Through Cancer funds AML research at MD Anderson
The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer ...
